A Phase 2a Study Assessing the Efficacy and Safety of STN1010905 Ophthalmic Suspension in Subjects with MGD

A Phase 2a, Randomized, Evaluator-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010905 Ophthalmic Suspension Compared with Placebo in Subjects with Meibomian Gland Dysfunction

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210371

Enrollment

Registered

2021-10-08

Start date

2021-10-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MGD (Meibomian Gland Dysfunction)

Interventions

Screening period : Artificial tear (BID, Both eyes) Treatment period : STN1010905 ophthalmic suspension or Placebo (BID, Both eyes)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatient Diagnosed as MGD Having ocular symptoms

Exclusion criteria

Exclusion criteria: Ocular disease which needs treatment expect MGD and DRYEYE Requires contact lenses wear during the study Any decision by the Investigator to terminate a subject in screening

Design outcomes

Primary

Measure	Time frame
Sign of Meibomian glands	—

Contacts

Public ContactYukie Migita

Santen pharmaceutical co.,ltd

clinical@santen.co.jp+81-6-4802-9341

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026